Sökning: WFRF:(Myhr Eriksson Kristina) >
Successful tyrosine...
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
-
- Flygt, Hjalmar (författare)
- Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
-
- Sandin, Fredrik (författare)
- Reg Canc Ctr, Uppsala, Sweden.,Regional Cancer Centre, Uppsala-Örebro, Sweden
-
- Dahlén, Torsten (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.
-
visa fler...
-
- Dreimane, Arta (författare)
- Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Region Östergötland, Hematologiska kliniken US,Univ Hosp, Dept Hematol, Linköping, Sweden.
-
- Lübking, Anna (författare)
- Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.,Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
-
- Markevärn, Berit (författare)
- Univ Hosp, Dept Hematol, Umeå, Sweden.,Department of Hematology, University Hospital, Umeå, Sweden
-
- Myhr-Eriksson, Kristina (författare)
- Sunderby Hosp, Dept Hematol, Luleå, Sweden.,Department of Hematology, Sunderby Hospital, Luleå, Sweden
-
- Olsson, Karin (författare)
- Reg Canc Ctr, Uppsala, Sweden.,Regional Cancer Centre, Uppsala-Örebro, Sweden
-
- Olsson-Strömberg, Ulla (författare)
- Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
-
- Själander, Anders (författare)
- Umeå universitet,Avdelningen för medicin,Umeå Univ, Dept Publ Hlth & Clin Med, Umeå, Sweden.
-
- Söderlund, Stina (författare)
- Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
-
- Wennström, Lovisa (författare)
- Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden.,Department of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden
-
- Wadenvik, Hans (författare)
- Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden.,Department of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden
-
- Stenke, Leif (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.
-
- Höglund, Martin (författare)
- Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
-
- Richter, Johan (författare)
- Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.,Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2021-03-30
- 2021
- Engelska.
-
Ingår i: British Journal of Haematology. - : John Wiley & Sons. - 0007-1048 .- 1365-2141. ; 193:5, s. 915-921
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://onlinelibrar...
-
https://umu.diva-por... (primary) (Raw object)
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007-2012, 548 had evaluable information on TKI discontinuation. With a median follow-up of nine years from diagnosis, 128 (23%) discontinued TKI therapy (>= 1 month) due to achieving a DMR (deep molecular response) and 107 (20%) due to other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those stopping in DMR, 49% re-initiated TKI treatment (median time to restart 4 center dot 8 months). In all, 38 patients stopped TKI within a clinical study and 90 outside a study. After 24 months 41 center dot 1% of patients discontinuing outside a study had re-initiated TKI treatment. TKI treatment duration pre-stop was longer and proportion treated with second-generation TKI slightly higher outside studies, conceivably affecting the clinical outcome. In summary we show that TKI discontinuation in CML in clinical practice is common and feasible and may be just as successful as when performed within a clinical trial.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- chronic myeloid leukaemia
- BCR‐
- ABL
- tyrosine kinase inhibitor
- discontinuation
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Flygt, Hjalmar
-
Sandin, Fredrik
-
Dahlén, Torsten
-
Dreimane, Arta
-
Lübking, Anna
-
Markevärn, Berit
-
visa fler...
-
Myhr-Eriksson, K ...
-
Olsson, Karin
-
Olsson-Strömberg ...
-
Själander, Ander ...
-
Söderlund, Stina
-
Wennström, Lovis ...
-
Wadenvik, Hans
-
Stenke, Leif
-
Höglund, Martin
-
Richter, Johan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
British Journal ...
- Av lärosätet
-
Uppsala universitet
-
Umeå universitet
-
Karolinska Institutet
-
Linköpings universitet